Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: A pilot study

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 11, 2008, Pages 1829-1837

  Derdemezis, C S ^a   Filippatos, T D ^a   Tselepis, A D ^b   Mikhailidis, D P ^c   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Ezetimibe; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Triglycerides; Visfatin

Indexed keywords

ATORVASTATIN; EZETIMIBE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VISFATIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; LIPID ABSORPTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PILOT STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PILOT PROJECTS; PYRROLES;

EID: 49649120178     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.11.1829     Document Type: Article

References (33)

1. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005;21:959-69
2. Kolovou GD, Dedoussis GV, Anagnostopoulou KK, et al. Management of a patient with a null low-density lipoprotein receptor mutation: a case report. Angiology 2006;57:729-32
3. Daskalopoulou SS, Milkhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis an absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006;22:511-28
4. Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94
5. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007;23:1169-76
6. Kalogirou M, Tsimihodimos V, Saougos V, et al. Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pretreatment. Arch Med Sci 2007;3:344-50
7. Luk T, Malam Z, Marshall JC: Pre-B cell colony-enhancing factor (PBEF)/ visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008;83:804-16
8. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005;11:344-7
9. Pilz S, Mangge H, Obermayer-Pietsch B, Marz W. Visfatin/Pre-B-cell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest 2007;30:138-44
10. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008;38:71-2
11. Filippatos TD, Derdemezis CS, Kiortsis DN, et al. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007;30:323-6
12. Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008;114:275-88
13. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006;10:851-66
14. 2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193:428-37
15. 2. Arterioscler Thromb Vasc Biol 2007;27:2236-43
16. Kostapanos MS, Derdemezis CS, Filippatos TD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008;578:249-52
17. Mauser W, Perwirz N, Meier B, et al. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol 2007;564:37-46
18. Wang P, Van Greevenbroek MM, Bouwman FG, et al. The circulating PBEF/ NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007;454:971-6
19. Sun G, Bishop J, Khalili S, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007;85:399-404
20. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183-92
21. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
22. Zhong M, Tan HW, Gong HP, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008
23. Ingelsson E, Larson MG, Fox CS, et al. Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 2007;30:1278-80
24. De Luis DA, Sagrado MG, Conde R, et al. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition 2008;24:517-21
25. 1. Clin Endocrinol (Oxf) 2006;65:667-72
26. Chen CC, Li TC, Li CI, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007;56:1216-20
27. Nakou E, Filippatos T, Liberopoulos E, et al. Effects of sibutramine plus verapamil SR/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharm 2008;9:1629-39
28. Oki K, Koide J, Nakanishi S, et al. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocrinol J 2007;54:431-5
29. Filippatos TD, Derdemezis CS, Georgoula M, et al. Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome. J Med Sci Res 2007;2:9-10
30. Pfutzner A, Hanefeld M, Lubben G, et al. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk - results from the PIOSTAT Study. Horm Metab Res 2007;39:764-8
31. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58
32. Takebayashi K, Suetsugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007;56:451-8
33. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007;115:972-80